18F FDG-PET/CT analysis of spread through air spaces (STAS) in clinical stage I lung adenocarcinoma

Ann Nucl Med. 2022 Oct;36(10):897-903. doi: 10.1007/s12149-022-01773-1. Epub 2022 Jul 12.

Abstract

Objective: The purpose of this retrospective study was to investigate the utility of F-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F FDG-PET/CT) to predict spread through air spaces (STAS) in clinical stage I lung adenocarcinoma.

Methods: Between April 2020 and January 2022, 52 patients (55 lesions) who underwent surgery for clinical stage I lung adenocarcinoma were enrolled. The lesions were divided into two groups according to the presence of STAS. 18F FDG-PET/CT parameters, specifically the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), were calculated. The SUVmax, MTV, and TLG were compared between the two groups upon surgical pathological examination. Receiver operating characteristic (ROC) curve analysis was performed to identify a cut-off value.

Results: Nineteen lesions (35%) were positive for STAS and 36 lesions were negative for STAS. According to the presence of STAS, significant differences were detected in the SUVmax (5.21 [range 1.52-16.50] vs. 2.42 [range 0.74-11.80], p = 0.0040) but not MTV (3.44 [range 0.65-24.36] vs. 2.95 [0.00-20.07], p = 0.20) and TLG (7.92 [range 0.93-47.82] vs. 5.63 [0.00-58.66], p = 0.14). SUVmax had an AUC value of 0.74 (95% CI 0.61-0.87) with a sensitivity of 89.5% and specificity of 52.8% at a cut-off of 2.48.

Conclusions: SUVmax rather than MTV and TLG were shown to be valuable indices for the prediction of STAS in clinical stage I lung adenocarcinoma.

Keywords: 18F FDG-PET/CT; 8th edition of UICC-TNM classification; Lung adenocarcinoma; STAS.

MeSH terms

  • Adenocarcinoma of Lung* / diagnostic imaging
  • Fluorodeoxyglucose F18
  • Glycolysis
  • Humans
  • Imidazoles
  • Lung Neoplasms* / pathology
  • Positron Emission Tomography Computed Tomography
  • Prognosis
  • Radiopharmaceuticals
  • Retrospective Studies
  • Tumor Burden

Substances

  • Imidazoles
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • xylometazoline